Trulicity and Bydureon are the first once WEEKLY GLP-1 agonists

March 2016

Trulicity (TRUE-lih-sih-tee, dulaglutide) and Bydureon (by-DUR-ee-on, exenatide ER) will be two new GLP-1 agonists for type 2 diabetes.

Injectable GLP-1 agonists are becoming more popular because they can lead to weight loss...and they rarely cause hypoglycemia.

Be familiar with how the GLP-1 agonists stack up.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cardiology Suggest an ACEI or an ARB for Hypertension or Diabetic Kidney Disease
Statins Use These Tips to Handle Confusing Statin Interactions
Diabetes Trulicity and Bydureon are the first once WEEKLY GLP-1 agonists
Diabetes Look Out for Rxs Written Just as "Insulin Glargine"
Anticoagulants Don't Assume DOACs are Preferred for All Patients with Venous Thromboembolism
Depression Recommend Combining Antidepressants from Different Classes
Vitamins & Minerals Explain Why Fewer Patients Will Have Vitamin D Blood Levels Drawn
Opioids stricter requirements for OTC codeine products
Tapering Don't Suggest Stopping Paroxetine "Cold Turkey"
Fungal Infections Caution About Fluconazole for Vaginal Candidiasis During Pregnancy
Med Adherence Think of Smartphone Apps as Another Tool in Your Adherence Toolbox
Needles & Syringes Use A 29- To 32-Gauge Needle For Most Insulins